With one of the relatively newer but important anti-diabetic drugs, Vildagliptin manufactured by Novartis, losing patent protection in December, dozens of companies are readying plans to launch the generic version to get a slice of the action in the growing Rs 13,000-crore diabetes therapy. The cost of therapy is expected to reduce by over 50%.

Read more

Every year many parents get surprised with the birth of an affected child with genetic disorders. “Genetic disorders are passed on from generations to generations. It runs in the family genes. Genes are very powerful when it comes to the birth of a child” Says Dr. Rajni Khajuria, lab director at Igenomix.

More inside